One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters)

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 1, 2007, Pages 153-160

  Češková, Eva ^a   Radovan, Přikryl ^a   Tomáš, Kašpárek ^a   Hana, Kučerová ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Firs episode schizophrenia; General psychopathology; Negative symptoms; Remission

Indexed keywords

BENZODIAZEPINE; BIPERIDEN; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 34249057454     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.1.153     Document Type: Article

References (16)

1. Addington J, Leriger E, Addington D. 2003. Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry, 48:204-7.
2. Andreasen NC, Carpenter WT Jr, Kane JM. et al. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry, 162:441-9.
3. Arango C, Buchanan RW, Kirkpatrick B, et al. 2004. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry, 19:21-6.
4. Češková E, Přiktyl R, Kašpárek T, et al. 2005. Psychopathology and treatment responsiveness of patients with first-episode schizophrenia. Neuropsychiatr Dis Treat, 1: 179-85.
5. Češková E, Přikryl li, Kašpárek T, et al. 2003. Prolactin levels in risperidone treatment of first-episode schizophrenia. Int J Psych Clin Pract, 8:1-6.
6. Kane JM, Krucht S, Carpenter D, et al. 2003. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry, 64(Suppl 12):6-19.
7. Kay S, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale for schizophrenia. Schizophr Bull, 13:261-78.
8. Keshavan MS, Rabinowith J, DeSmedt G. et al. 2004. Correlates of insight in first episode psychosis. Schizophr Res, 70:187-94.
9. Lieberman JA, Tollefson GD, Tohen M. et al. 2003. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry, 160:1396-404.
10. Malla AK, Norman RMG, Machanda R. et al. 2002. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv, 53:458-63.
11. Novak-Grubic V, Tavcar R. 1999. Treatment compliance in first-episode schizophrenia [letter]. Psychiatr Serv, 50:970-1.
12. Peralta V, Cuesta MJ, Martinez-Larrea A, et al. 2000. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry, 157:1461-6.
13. Přikryl R, Češková E, Kašpárek T, et al. 2006. Neurological soft sings, clinical symptoms and treatment reactivity in patiens suffering from first episode schizophrenia. J Psych Res, 40:141-6.
14. Robinson DG, Woerner MG, Alvir JMJ, et al. 1999. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatyy, 156:544-49.
15. Scottish Schizohrenia Research Group. 1987. The Scottish first episode schizophrenia study. Br J Psychiatry, 150:334-8.
16. Verdoux H, Lengronne J, Liraud F. et al. 2000. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand, 102:203-10.